Interobserver reproducibility for HER2/neu immunohistochemistry: A comparison of reproducibility for the HercepTest™ and the 4B5 antibody clone

Pathology Research and Practice

Volumn 212, Issue 3, 2016, Pages 190-195

  Layfield, Lester J ^a   Frazier, Shellaine ^a   Esebua, Magda ^a   Schmidt, Robert L ^b  

^a University of Missouri   (United States)

^b ARUP LABORATORIES   (United States)

Author keywords

4B5; Breast carcinoma; HER2; HercepTest ; Immunohistochemistry; Interobserver reproducibility

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4B5; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; INTEROBSERVER REPRODUCIBILITY; LABORATORY DEVICE; REPRODUCIBILITY; TISSUE SECTION; BREAST NEOPLASMS; COMPARATIVE STUDY; FEMALE; OBSERVER VARIATION; PROCEDURES; STANDARDS;

ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; OBSERVER VARIATION; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 84959353151     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2015.11.016     Document Type: Article

References (16)

1. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25(January (1)):118-145. American Society of Clinical Oncology; College of American Pathologists.
2. Paik S., Bryant J., Tan-Chiu E., Romond E., Hiller W., Park K., Brown A., Yothers G., Anderson S., Smith R., Wickerham D.L., Wolmark N. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J. Natl. Cancer Inst. 2002, 94(June (11)):852-854.
3. Isola J., Tanner M., Forsyth A., Cooke T.G., Watters A.D., Bartlett J.M. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin. Cancer Res. 2004, 10(July (14)):4793-4798.
4. Roche P.C., Suman V.J., Jenkins R.B., Davidson N.E., Martino S., Kaufman P.A., Addo F.K., Murphy B., Ingle J.N., Perez E.A. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J. Natl. Cancer Inst. 2002, 94(June (11)):855-857.
5. Hsu C.Y., Ho D.M., Yang C.F., Lai C.R., Yu I.T., Chiang H. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am. J. Clin. Pathol. 2002, 118(November (5)):693-698.
6. Lacroix-Triki M., Mathoulin-Pelissier S., Ghnassia J.P., Macgrogan G., Vincent-Salomon A., Brouste V., Mathieu M.C., Roger P., Bibeau F., Jacquemier J., Penault-Llorca F., Arnould L. High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study. Eur. J. Cancer 2006, 42(November (17)):2946-2953.
7. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:1-28.
8. Mamoon N., Syed F.N., Mushtag S., Nasir H., Ahmad I.N. Interobserver variability in HER2/neu reporting on immunohistochemistry in breast carincomas. J. Pak. Med. Assoc. 2014, 64(2):151-154.
9. Al Haddabi I., Qureshi A., Saparamadu A., Al Hamdani A., Al Riyami M., Ganguly S. Inter-observer agreement in reporting HER 2 Neu protein over expression by immunohistochemistry. Indian J. Pathol. Microbiol. 2014, 57(April-June (2)):201-204.
10. van der Vegt B., de Bock G.H., Bart J., Zwartjes N.G., Wesseling J. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod. Pathol. 2009, 22(July (7)):879-886. 10.1038/modpathol.2009.37.
11. Powell W.C., Hicks D.G., Prescott N., Tarr S.M., Laniauskas S., Williams T., Short S., Pettay J., Nagle R.B., Dabbs D.J., Scott K.M., Brown R.W., Grogan T., Roche P.C., Tubbs R.R. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl. Immunohistochem. Mol. Morphol. 2007, 15(March (1)):94-102.
12. Kakar S., Puangsuvan N., Stevens J.M., Serenas R., Mangan G., Sahai S., Mihalov M.L. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol. Diagn. 2000, 5(September (3)):199-207.
13. Rhodes A., Sarson J., Assam E.E., Dean S.J., Cribb E.C., Parker A. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am. J. Clin. Pathol. 2010, 134(October (4)):621-632.
14. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33(March (1)):159-174.
15. Vergara-Lluri M.E., Moatamed N.A., Hong E., Apple S.K. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod. Pathol. 2012, 25(October (10)):1326-1332.
16. Gavrielides M.A., Gallas B.D., Lenz P., Badano A., Hewitt S.M. Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy. Arch. Pathol. Lab. Med. 2011, 135(February (2)):233-242.